Show Summary Details
Page of

BPH, PSA, and the risk of having prostate cancer (PCA) 

BPH, PSA, and the risk of having prostate cancer (PCA)
BPH, PSA, and the risk of having prostate cancer (PCA)

Seife Hailemariam

and Lukas Bubendorf

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 15 January 2021

Benign prostatic hyperplasia (BPH) is a common benign disorder of the prostate that, when advanced, results in varying degrees of urinary obstruction with lower urinary tract symptoms (LUTS)

The disease represents a nodular enlargement of the prostate mainly in the transition zone (TZ) caused by hyperplasia of both glandular and stromal components

It occurs only in individuals with intact testes indicating androgen dependency

Despite topographic and architectural similarities between PCA arising in TZ and atypical adenomatous hyperplasia (AAH) and BPH, there is no convincing evidence linking BPH or AAH to PCA.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.